3,956
Views
53
CrossRef citations to date
0
Altmetric
Brief Report

CD20-selective inhibition of CD47-SIRPα “don't eat me” signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab

, , , , , , , , , , & show all
Article: e1386361 | Received 02 Aug 2017, Accepted 24 Sep 2017, Published online: 31 Oct 2017

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

For more information please visit our Permissions help page.